Skip to content

Vacuum Erection Device in Improving Recovery of Erectile Function in Patients With Prostate Cancer Undergoing Surgery

Analysis of Technique Comparison With a Vacuum Erection Device as Part of an Erectile Rehabilitation Program Following Robotic Radical Prostatectomy: A Randomized Comparison of Methodology

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01660152
Enrollment
2
Registered
2012-08-08
Start date
2011-09-30
Completion date
2013-07-17
Last updated
2017-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male Erectile Disorder, Prostate Cancer, Sexual Dysfunction

Keywords

male erectile disorder, prostate cancer, Laparoscopic prostatectomy

Brief summary

The purpose of this study is to determine which technique in using a vacuum erection device (VED) is best. Erectile dysfunction (ED) after robotic prostate cancer surgery is a concern for both the surgeon and the patient. Recent studies have shown that beginning to use the vacuum pump on a daily basis starting with in 2-8 weeks may help prevent the start of penile shrinkage. This is a potential issue that can occur because of decreased blood flow after prostate cancer surgery. This study will allow researchers to determine and compare vacuum therapy techniques and erectile function outcomes of patients who have prostate cancer surgery

Detailed description

PRIMARY OBJECTIVES: I. Determine sexual function and penile morphometric outcomes for the post-robotic-assisted laparoscopic prostatectomy (RALP) patients undergoing daily vacuum therapy using one of two randomized methods and whether these outcomes differ. SECONDARY OBJECTIVES: I. Compare compliance rates between the two randomized groups using the compliance questionnaire and a diary collected from patients at each follow up visit. II. Compare overall patient satisfaction with the recovery procedure between the two randomized groups utilizing the SHIM (Sexual Health Inventory for Men) questionnaire. OUTLINE: Patients are randomized to 1 of 2 treatment groups. GROUP A: Patients receive vacuum therapy daily over 10 minutes while holding erection for 2 minutes after undergoing RALP. Patients complete erection process 5 times. GROUP B: Patients receive vacuum therapy daily over 10 minutes while holding erection for 5 minutes after undergoing RALP. Patients complete erection process 2 times. After completion of study treatment, patients are followed up at 3, 6, and 12 months.

Interventions

OTHERSexual Health Inventory for Men (SHIM) questionnaire administration

Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.

PROCEDUREmanagement of therapy complications

Receive VED

PROCEDUREDaily vacuum therapy

Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.

Sponsors

Ohio State University Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
No minimum to 70 Years
Healthy volunteers
No

Inclusion criteria

* Sexually active men without the consistent use of erectile aids pre-operatively (i.e. oral pharmacotherapy, intraurethral prostoglandin E1 \[PGE1\], intracavernosal injection therapy and penile implants) * Undergoing a bilateral nerve sparing robotic prostatectomy * Pre-operative baseline SHIM total score of greater than or equal to 17 * Presence of a female sexual partner * Dexterity necessary to operate vacuum pump

Exclusion criteria

* Has a history of cardiac failure, angina, or life-threatening arrhythmia within the past 6 months * Has taken or has been prescribed nitrate medication in any form in the last 6 months * Has a known sensitivity to Phosphodiesterase type 5 inhibitors such as Sildenafil, Tadalafil or Vardenafil * Men with sickle cell anemia * Men with insufficient manual dexterity to operate vacuum device * Men with a history of known penile deformity or Peyronie's disease * Pre or postoperative androgen therapy * Pre or postoperative radiation therapy to pelvic area * Men actively smoking at time of enrollment, 1 pack per day or more

Design outcomes

Primary

MeasureTime frameDescription
Changes in sexual function based on the self reported SHIM assessment and penile morphometric outcomes based on penile dimension measurements at rest3 months post-surgerySummarized according to assigned treatment group. Linear mixed models will be used to model the changes over time.

Secondary

MeasureTime frameDescription
Compliance and overall patient satisfaction (1 to 25 point scale) based on the self reported compliance diary and SHIM questionnairesUp to 12 months post-surgerySummarized according to assigned treatment group.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026